Literature DB >> 26796098

Visceral Leishmaniasis: Kala-azar.

R V Nampoothiri1, S Sreedharanunni2, B A Chhabria3, S Jain3.   

Abstract

Entities:  

Year:  2016        PMID： 26796098      PMCID： PMC4888333          DOI： 10.1093/qjmed/hcw005

Source DB:  PubMed          Journal:  QJM        ISSN： 1460-2393


× No keyword cloud information.
  5 in total

Review 1.  U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.

Authors:  A Meyerhoff
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

2.  Kala-azar--progress against a neglected disease.

Authors:  Henry W Murray
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

Review 3.  Laboratory diagnosis of visceral leishmaniasis.

Authors:  Shyam Sundar; M Rai
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

4.  Hematologic changes in visceral leishmaniasis/kala azar.

Authors:  Neelam Varma; Shano Naseem
Journal:  Indian J Hematol Blood Transfus       Date:  2010-09-30       Impact factor: 0.900

Review 5.  Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease.

Authors:  Marleen Boelaert; Kristien Verdonck; Joris Menten; Temmy Sunyoto; Johan van Griensven; Francois Chappuis; Suman Rijal
Journal:  Cochrane Database Syst Rev       Date:  2014-06-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.